Skip to content

Impact of Intravenous Lidocaine During Colorectal Surgery on Pain and Immune Functions

Intravenous Lidocaine and Immunity

This study evaluates the impact of intraoperative intravenous lidocaine administered during laparoscopic colorectal surgery on the intraoperative remifentanil consumption as well as postoperative pain and opioid requirements. It will evaluate immune cell activity for 48hours after surgical stress and general anesthesia with or without intravenous lidocaine.

null

Participation Requirements

  • Sex:

    ALL

  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria:

* ASA status I, II or III
* Patients older than 18 years
* Colonic surgery
* Classical management of ERAS program patients in our center

Exclusion Criteria:

* Arrhythmia, abnormal electrocardiographic , antiarrhythmic therapy
* Immunosuppressive treatments, corticosteroids or long-term NSAIDs (multiple weekly doses) or during preoperative 48 hours
* conversion intraoperative of a laparoscopic surgical technique to a laparotomy technique
* Pregnant women
* Inability to complete the questions related to this study
* Inability to use hydromorphone postoperative PCA
* Intolerance or allergy to lidocaine, hydromorphone or any other drug that is included in the protocol for perioperative management

Unexpected events leading to the exclusion:

* Difficult unplanned intubation
* Surgical complication requiring aggressive haemodynamic support (vasopressors, inotropes, transfusion)

Study Location

Hôpital Maisonneuve-Rosemont, CIUSSS de l'Est de l'Ile de Montréal
Hôpital Maisonneuve-Rosemont, CIUSSS de l'Est de l'Ile de Montréal
Montréal, Quebec
Canada

Contact Study Team

Primary Contact

Philippe Richebe, MD, PhD

[email protected]
514-743-6558
Study Sponsored By
Ciusss de L'Est de l'Île de Montréal
Participants Required
More Information
Study ID: NCT03410836